User profiles for C. Hatzis
 | Christos HatzisAssociate Professor Adjunct of Medicine, Yale School of Medicine, Yale Cancer Center Verified email at yale.edu Cited by 10677 |
[HTML][HTML] Multigene prognostic tests in breast cancer: past, present, future
There is growing consensus that multigene prognostic tests provide useful complementary
information to tumor size and grade in estrogen receptor (ER)-positive breast cancers. The …
information to tumor size and grade in estrogen receptor (ER)-positive breast cancers. The …
Commercialized multigene predictors of clinical outcome for breast cancer
… The luminal group was subsequently subdivided into luminal-A and luminal-B (with a
luminal-C group added and then removed). Luminal-A tumors have the highest ER expression …
luminal-C group added and then removed). Luminal-A tumors have the highest ER expression …
[PDF][PDF] Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
WF Symmans, F Peintinger, C Hatzis, R Rajan… - J clin Oncol, 2007 - academia.edu
… The bias-adjustedc-index in the development cohort was estimated to be 0.77 (95% CI, 0.69
to 0.84), indicating statistically significant discrimination (c 0.5 for random predictions, c 1 for …
to 0.84), indicating statistically significant discrimination (c 0.5 for random predictions, c 1 for …
Enhancing reproducibility in cancer drug screening: how do we move forward?
… Christos Hatzis … C. Hatzis was supported by Yale University. PL Bedard was supported
by a grant from the United States National Institute of Health (UM1 CA186644). N. …
by a grant from the United States National Institute of Health (UM1 CA186644). N. …
[HTML][HTML] Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype
… Note that the original development cohort (cohort 1, Table 1) was included in the analysis
for plots A to C. The length of each x-axis is proportional to the duration of follow-up of survivors…
for plots A to C. The length of each x-axis is proportional to the duration of follow-up of survivors…
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
… Statistical Analysis: Dr Hatzis conducted all analyses for signature development for the
discovery cohort. Dr Wang had full access to all data from the validation cohort and conducted …
discovery cohort. Dr Wang had full access to all data from the validation cohort and conducted …
[HTML][HTML] Immunological differences between primary and metastatic breast cancer
Background Little is known about how the immune microenvironment of breast cancer
evolves during disease progression. Patients and methods We compared tumor infiltrating …
evolves during disease progression. Patients and methods We compared tumor infiltrating …
[HTML][HTML] Genomic index of sensitivity to endocrine therapy for breast cancer
Purpose We hypothesize that measurement of gene expression related to estrogen receptor
α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral …
α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral …
[HTML][HTML] Common contaminants in next-generation sequencing that hinder discovery of low-abundance microbes
Unbiased high-throughput sequencing of whole metagenome shotgun DNA libraries is a
promising new approach to identifying microbes in clinical specimens, which, unlike other …
promising new approach to identifying microbes in clinical specimens, which, unlike other …
[PDF][PDF] Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
…, Y Qi, J Matsuoka, EJ Yang, GN Hortobagyi, C Hatzis… - J Clin Oncol, 2012 - academia.edu
Purpose We examined borderline estrogen receptor (ER)–positive cancers, defined as having
1% to 10% positivity by immunohistochemistry (IHC), to determine whether they show the …
1% to 10% positivity by immunohistochemistry (IHC), to determine whether they show the …